Pradaxa is a medication that was released in the United States by Daiichi Sankyo Co., Ltd. to treat patients with bleeding ulcers, and other side effects of non-healing wounds, including gastrointestinal hemorrhage. Pradaxa has been associated with serious adverse reactions such as heart attack or stroke when taken shortly after having eaten within three hours of taking Pradaxa. The FDA approved the use of this drug despite these risks because it had already been marketed in Europe for several years without any evidence of major incidents or deaths related to its use outside an artificial laboratory setting
The “pradaxa lawsuit update 2020” is a legal document that discusses the latest updates in the “pradaxa lawsuit.” The lawsuit was filed by patients who had been prescribed Pradaxa.
Thousands of adverse events and over 1,000 deaths have been related to Pradaxa, for which Boehringer Ingelheim has already paid $650 million.
The blood thinner Pradaxa (dabigatran) has been associated to thousands of adverse events and over 1,000 deaths since its FDA approval in 2010. Thousands of lawsuits resulted from these injuries and deaths. Approximately 4,000 claims made by Pradaxa patients were merged into a multidistrict action in August 2012. (MDL).
Boehringer Ingelheim settled all of its 4,000 cases for $650 million in May 2014. (The business had paid the US government $95 million eighteen months before, in October 2012, to resolve a whistleblower complaint over its off-label marketing of multiple medications.)
But it wasn’t until October 2015 that the FDA authorized Praxbind (idarucizumab), an antibody that has been demonstrated to counteract Pradaxa’s anticoagulant effects.
That implies that Pradaxa victims did not get any compensation from the drugmaker for over a year and a half, and they still had no antidote for the drug’s hemorrhages.
If you weren’t a part of the 2014 settlement and took Pradaxa before Praxbind was released last autumn, you may be eligible for damages compensation.
Participate in the Lawsuit
Pradaxa (dabigatran) is an anticoagulant (blood thinner) made by Boehringer Ingelheim, a German pharmaceutical firm. Pradaxa was authorized by the FDA in October 2010 for the prevention of strokes in individuals with atrial fibrillation (a-fib).
Prior to the approval of Pradaxa, warfarin enjoyed a 60-year monopoly on the blood thinner market. Pradaxa, unlike warfarin, does not need constant blood monitoring. Pradaxa has been prescribed to about 725,000 people in the United States by 2012.
Unfortunately, there was no means to cure a serious bleeding incident caused by Pradaxa until 2015. (Vitamin K may prevent warfarin-related events.) Thousands of bad occurrences occurred as a consequence, and hundreds of people died as a result of excessive bleeding.
According to a research published in the British Medical Journal, Boehringer Ingelheim withheld critical safety information from Pradaxa patients.
Pradaxa has been related to over 1,000 fatalities by February 2014. In May of that year, Boehringer Ingelheim settled all of its 4,000 cases for $650 million. (The business had paid the US government $95 million eighteen months before, in October 2012, to resolve a whistleblower complaint over its off-label marketing of multiple medications.)
The British Medical Journal (BMJ) issued a paper in July 2014 stating that Boehringer Ingelheim concealed critical data showing that monitoring Pradaxa patients’ plasma levels might enhance the drug’s safety.
Finally, in October 2015, the FDA authorized Praxbind (idarucizumab), an antibody that has been demonstrated to swiftly reverse Pradaxa’s anticoagulation effects, potentially saving a patient’s life in the case of a significant bleeding episode.
Pradaxa’s permitted uses were increased by the FDA in November 2015 to include the prevention of venous thromboembolism (VTE) in patients who had recently had knee or hip replacement surgery.
Pradaxa Litigation History
Boehringer Ingelheim settled all of its 4,000 cases for $650 million in 2014.
Pradaxa sufferers began filing wrongful death and personal damage claims against the company as early as 2010. Approximately 4,000 claims made by Pradaxa patients were merged into a multidistrict action in August 2012. (MDL).
Pradaxa has been related to over 1,000 fatalities by February 2014. Boehringer Ingelheim agreed to pay $650 million to resolve all of its 4,000 claims in May, under pressure from plaintiffs, health experts, and the media.
Since then, there have been no reported settlements, so it’s unknown how much compensation a plaintiff in 2016 may obtain. The major issue with Pradaxa was that it didn’t have an antidote for bleeding incidents, which didn’t alter until Praxbind was released in the fall of 2015.
As a result, a patient who had significant hemorrhaging or another Pradaxa-related harm between May 2014 and October 2015 should have the same legal standing as any other participant of the $650 million settlement (provided they were not part of that settlement, of course).
Eligibility for a Lawsuit and Compensation
If you or a loved one was hurt by Pradaxa before Praxbind was released last autumn and you were not a part of the 2014 Pradaxa settlement, you may be eligible for payments. The following expenses may be covered by these monetary awards:
- Suffering and pain
- Medical expenses
- Wages lost and other monetary losses
- In the case of a loved one’s death, funeral costs will be incurred.
After over a thousand deaths linked to Pradaxa, it’s incredible that neither Boehringer Ingelheim nor the FDA ever removed the drug off the market. The antidote for Pradaxa was many years late, and hundreds of individuals died as a consequence.
See whether you have a case.
For a Free Legal Consultation, Please Contact Us.
Our skilled legal team at ClassAction.com assists consumers in holding drug corporations responsible for their harmful and faulty products. We’ve handled these issues for decades and know how to get victims the compensation they deserve.
We’ve helped over 200,000 customers win over $2 billion in settlements and awards, and we only get paid if your case is satisfactorily resolved.
You may be eligible to compensation for emotional anguish, medical costs, and other damages if you or a loved one had a serious bleeding incident after taking Pradaxa. Please contact us right away to see whether you are entitled for compensation.
Watch This Video-
The “pradaxa settlement checks” is a lawsuit against Pradaxa. The drug was released in 2011 and has been linked to severe bleeding problems. The plaintiff, who is suing Novartis, the maker of Pradaxa, says that they were not warned about this side effect.
Frequently Asked Questions
Is there a recall on Pradaxa?
A: There is not a recall on Pradaxa.
How long has Pradaxa been on the market?
A: Pradaxa has been on the market for about 6 years, but it was first released in 2011.
Who manufactures Pradaxa?
A: Pradaxa is a medication that was manufactured by Sanofi, who acquired the rights to the drug from Boehringer Ingelheim.
- pradaxa lawsuit 2021
- pradaxa lawsuit settlement amounts
- pradaxa settlement payout 2021
- pradaxa lawsuit timeline
- recent pradaxa settlement